SCHEMBL10132085

SCHEMBL10132085

O=C(CCC(=O)NC1CC1)NC1CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.65
ALDH1A1 P00352 3/20 0.64
HPGD P15428 3/20 0.56
HDAC3 O15379 2/20 0.54
HDAC1 Q13547 2/20 0.54
HDAC2 Q92769 2/20 0.54
HDAC10 Q969S8 2/20 0.54
HDAC11 Q96DB2 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
NCOR2 Q9Y618 1/20 0.54
KMT2A Q03164 4/20 0.48
EPHX1 P07099 1/20 0.48
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
LMNA P02545 1/20 0.47
EPHX2 P34913 1/20 0.46
SMYD3 Q9H7B4 1/20 0.46
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10015691 0.90 ALDH1A1 (0.80) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL13544828 0.88 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL6003415 0.87
SCHEMBL6003417 0.87
SCHEMBL10587847 0.87 ALDH1A1 (0.83) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL6874316 0.85
SCHEMBL2240946 0.85
SCHEMBL20581686 0.85 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1HPGDHDAC3HDAC1
SCHEMBL5988081 0.85
SCHEMBL6245526 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20100048488-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS, INC. 2010-02-25 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A SMN1; SMN2 4722/4885ALDH1A1 4835/4885HPGD 3932/4885
US-20100048488-A1 IMMUNOMODULATORY PEPTIDES FCGRT, FCGR3B, FCGR2A SMN1; SMN2 3809/4885ALDH1A1 4561/4885HPGD 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.